David Din, CFA

Investor in PLTR, IBRX, ONDS and EOSE. Former banker and buy-side analyst at UBS . I care about Alzheimer and alternative medicine.

[David Din, CFA @DavidDin]

@cantonmeow Hehehe

[David Din, CFA @DavidDin]

@cantonmeow @elonmusk Thank God you are driving a Tesla with FSD!

[David Din, CFA @DavidDin]

@LoriMills4CA42 Well done!

[David Din, CFA @DavidDin]

@Deepvalue69420 @JJB_VIII @joerogan @joeroganhq @JamieVernon Yes he is!

[David Din, CFA @DavidDin]

@Deepvalue69420 @USNCG5Rick @JJB_VIII @joerogan @joeroganhq @JamieVernon The worst he could do is challenge you to a UFC fight…

[David Din, CFA @DavidDin]

@USNCG5Rick Yes, of course!

[David Din, CFA @DavidDin]

@USNCG5Rick Thank you very much, Rick and Bullish!

And I do believe there is also a Rick in Casablanca. So you two guys belong together!

[David Din, CFA @DavidDin]

@sergiumogan @teslaeurope FSD unsupervised in Switzerland is what the Swiss regulators are demanding. Bring it on!

[David Din, CFA @DavidDin]

$IBRX

The good news keeps coming. Step for step.

[David Din, CFA @DavidDin]

@MaryBschanck The FDA might not realize it, but this might be its biggest test yet.

[David Din, CFA @DavidDin]

@Deepvalue69420 @DrPatrick Well done!

[David Din, CFA @DavidDin]

@Berlinergy @DrPatrick Genau

[David Din, CFA @DavidDin]

$IBRX

I cannot be the only one who has noticed how young and energetic our good doctor @DrPatrick looks.

He has stated that he took Anktiva during the Covid time, and that he never jad the virus, because the BioShield would have cleared the virus immediately.

But Anktiva also gave him longevity in my view.

Check out this article where they seem to have found something that is clearing senescent cells and reversing biological aging. I would not be surprised if Anktiva has the same effect. How about a trial where they are targeting metabolic aging as the indication itself?

And this does not only work in humans, but also in dogs. As the proud father of a a wonderful and lovely dog, I would do anything for my Lucky.

[Jason R. Williams, MD, DABR @jasonwilliamsmd]

When I started doing intratumoral immunotherapy years ago, I noticed something I wasn't expecting. Some of my patients seemed to be getting younger. Not just responding to cancer treatment, actually looking and functioning younger. That observation is what pulled me into longevity medicine in the first place. The drugs activating the immune system against cancer were also clearing senescent cells and reversing biological aging in the same patients.

Which is why this dog study matters more than people realize. LOY-002 isn't treating a disease. It's targeting metabolic aging as the indication itself. That's a regulatory first, and it only happened because the veterinary side moves faster than the human side does on questions like this.

The same biology drives both processes. Senescent cell accumulation. Immune decline. Chronic inflammation. Mitochondrial dysfunction. Cancer is a disease of the aged cell, not the aged person. Which is why we're now seeing it in 30 year olds. Whatever Loyal learns over the next four years is going to flow upstream into how we think about intervention in humans.

The cancer field and the longevity field have been treated as separate conversations for a long time. They were never separate. This study is one of the first regulatory acknowledgments of that.

[David Din, CFA @DavidDin]

@FDAOncology Anktiva most likely also works for “ultra-rare cancers “. But you know that. You just don’t care about cancer patients.

[David Din, CFA @DavidDin]

@Deepvalue69420 Thanks Ghost

[David Din, CFA @DavidDin]

$ IBRX

It’s been a long time since I have posted any charts of mine.

Today we almost dropped below the support in my chart.

[David Din, CFA @DavidDin]

@Sandiithiko Hehehe. So that’s how it feels!

[David Din, CFA @DavidDin]

Gee, I just found my twin on X. I wonder what his plan might be?

[David Din, CFA @DavidDin]

@Sandiithiko Your wish has been fulfilled

[David Din, CFA @DavidDin]

@dannycheng2022 I am having a vacation and really enjoying posting about my favorite company ImmunityBio.

Thank you very much Danny, and say hello to Dr Cat!

[David Din, CFA @DavidDin]

$IBRX

It’s been a while since we heard news from Saudi Arabia.

I am looking forward to see how much revenue will come from them in 2026.

And Saudi definitely remains the dark horse when it comes to authorizing new approvals for Anktiva. The one approval the world is waiting for is for Lymphopenia.

[GainzAlgo @gainzalgo]

$IBRX Even Saudi users are criticizing the FDA. This was translated from X/Twitter.